RxDoctor Payments Data

Noah Whetstone, MD

Internal Medicine · Mobile, ALNPI 1508818675

Payments from drug & device makers

$10,761in general payments, 2019–2025

Across 793 payments — averaging $13.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • GSK$869
  • Pfizer$747
  • Boehringer Ingelheim$629
  • Bayer$567
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$10,62299%
  • Education$1391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,761 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$206,870
Medicare patients
433
Services billed
9,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$161,767
JanuviaSitagliptin Phosphate83$96,988
OzempicSemaglutide75$80,311
XareltoRivaroxaban59$59,776
MounjaroTirzepatide42$56,069
LinzessLinaclotide60$54,836
JardianceEmpagliflozin43$51,784
EntrestoSacubitril/Valsartan20$24,406
RybelsusSemaglutide13$23,659
TradjentaLinagliptin19$21,887
TrulicityDulaglutide18$21,872
JanumetSitagliptin Phos/Metformin Hcl19$21,304
MyrbetriqMirabegron16$19,320
Humalog Kwikpen U-200Insulin Lispro12$18,960
Breo ElliptaFluticasone/Vilanterol29$14,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$747$161,767185 claims
MerckJanuvia, Janumet$71$118,292102 claims
Novo NordiskOzempic, Rybelsus$1,638$103,96988 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Spiriva Respimat$629$97,24489 claims
Lilly USA, LLCMounjaro, Trulicity$468$77,94160 claims
Johnson & JohnsonXarelto$530$59,77659 claims
AbbVieLinzess$1,717$54,83660 claims
AstraZenecaSymbicort, Brilinta, Breztri Aerosphere$499$28,55463 claims
NovartisEntresto$438$24,40620 claims
Astellas Pharma US IncMyrbetriq$228$19,32016 claims
GSKBreo Ellipta$869$14,82229 claims
Scilex Pharmaceuticals Inc.Colchicine$21$5,82958 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →